SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

PN-881

PTGX·Protagonist Therapeutics, Inc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1 completed; Phase 2b planned
Time to market
If Phase 2b initiates in 2027 and proceeds smoothly, a potential approval would likely be several years away (estimated 2029-2031), assuming positive data across Phase 2b and Phase 3 trials.
Why 3/10
No hard, dated binary catalyst is scheduled in the next ~12 months. PN-881 has completed Phase 1, and a comprehensive Phase 2b program for psoriasis is planned but not yet initiated with no specific start date announced. The drug is an early-stage pipeline asset at a company with two already-approved, revenue-generating products, so it is not a near-term value driver.
Actionable Insight NEUTRAL

Watch for the initiation of the Phase 2b psoriasis program, which the company has guided as planned. Positive Phase 1 safety/tolerability data could support a rapid move into Phase 2b. As a wholly-owned asset at a now-profitable company with two approved drugs, PN-881 represents pipeline upside but is not a near-term binary catalyst.

Price Chart

Loading chart...

Executive Summary

PN-881 is an oral peptide IL-17 antagonist being developed by Protagonist Therapeutics (NASDAQ: PTGX) for psoriasis and potentially other IL-17-mediated inflammatory diseases. It is a wholly-owned asset (not partnered), unlike the company's two approved drugs ICOTYDE (icotrokinra, partnered with J&J) and rusfertide (partnered with Takeda). PN-881 was nominated as a development candidate in November 2024, completed its Phase 1 SAD/MAD study by mid-2026, and the company has guided a comprehensive Phase 2b program for psoriasis as the next step. Preclinical data showed potency comparable to the injectable biologic bimekizumab and roughly 70-100 fold greater than secukinumab. As an early-stage pipeline asset at a now-profitable company with two revenue-generating approved products, PN-881 represents long-term pipeline upside rather than a near-term binary catalyst.

How It Works

PN-881 is an oral (pill) peptide drug that blocks the IL-17 pathway, a key driver of inflammation in psoriasis and other autoimmune diseases. It works by binding to and neutralizing IL-17 proteins (the AA, FF and AF forms) that trigger skin inflammation. Unlike current IL-17 blockers which are injections or infusions, PN-881 is designed to be taken orally as a peptide, which could be more convenient for patients.

Trial Status

PN-881 was nominated as a development candidate in November 2024. A Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study (NCT07153146) began in late 2025 and was completed by August 2026. The company has announced plans for a comprehensive Phase 2b program in psoriasis but has not yet provided a specific start date.

The Two-Sided Case

▲ Bull Case5
PN-881 is a wholly-owned oral peptide IL-17 antagonist with preclinical data showing potency comparable to bimekizumab and roughly 70-100 fold greater than secukinumab, suggesting best-in-class potential.
Protagonist has a proven oral peptide platform (icotrokinra/ICOTYDE already FDA-approved), de-risking the technology for PN-881.
The company is now profitable with $220M net income in Q3 2026 and has strong cash flow from two approved drugs (ICOTYDE and rusfertide), providing ample funding for PN-881 development without dilution.
Analyst consensus is overwhelmingly bullish (20 Buy/Strong Buy vs 1 Hold, mean price target $182 vs $132 current price, implying 38% upside).
As a wholly-owned asset, PN-881 offers Protagonist 100% of any future economics, unlike their partnered programs (icotrokinra with J&J, rusfertide with Takeda).
▼ Bear Case4
PN-881 is still in early clinical development (Phase 1 completed, Phase 2b not yet initiated) and faces a long, expensive development path before any potential approval.
The IL-17 inhibitor market is crowded with approved injectable biologics (Cosentyx, Taltz, Bimzelx) from large pharma; an oral peptide will need to demonstrate a clear efficacy/safety advantage to capture share.
CEO Dinesh Patel sold shares worth approximately $17.5M in September 2026 under a 10b5-1 plan, and CFO Ali Asif also sold shares, which may signal insider caution about near-term valuation.
Several institutional investors (Citadel, Adage Capital, Rubric Capital) exited PTGX positions in Q2 2026, suggesting some profit-taking after the stock's multi-year run.

Upcoming Catalysts

  • Initiation of Phase 2b clinical program for psoriasis (timing not yet specified)
  • Potential presentation of Phase 1 safety/tolerability data at a medical conference

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Protagonist Therapeutics, Inc 8-K PTGX ·Originating report

Sources · 6

Hover a chip for the title
1 freep.com2 theglobeandmail.com3 finanznachrichten.de4 usatoday.com5 seekingalpha.com6 investing.com